Marlborough, Mass.-based Boston Scientific plans to acquire Nalu Medical, a privately held company that developed a battery-free implantable neurostimulation system, according to an Oct. 17 press release.
Boston Scientific said the agreement includes an upfront cash payment of $850 million, with up to $100 million in additional payments contingent on sales-based milestones over the next three years. The transaction is expected to close in the first half of 2025.
The acquisition expands Boston Scientific’s neuromodulation portfolio, which includes spinal cord stimulation and dorsal root ganglion systems. The company reported approximately $675 million in 2023 sales from its neuromodulation business.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.